ReviewInternational journal of nanomedicine2026
Nanoformulated Phytochemicals Against Pancreatic Cancer: Emerging Advances in Therapeutic Strategies.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic cancer (PC) is an aggressive malignancy that has become one of the leading causes of cancer-related death worldwide. Remarkably, phytochemical-based nanoformulations have demonstrated great potential in combating cancer progression. Therefore, the objective of this scoping review is to analyze the most recent advances in the application of nanoformulated phytochemicals against PC. Methods: This scoping review included English-language articles published between 2018 and 2025 that reported advances in the development of phytochemical-based nanoformulations and their therapeutic evaluation in PC biological models. On the contrary, nanoformulation studies focused on cancers other than PC were excluded, as were those based solely on computational analyses or addressing a phytochemical or a nanoplatform without combining both into a nanoformulation. Different types of scientific communication, such as reviews, book chapters, commentaries, and news, were not considered. The literature searches were conducted across 6 databases, including Scopus, Web of Science, and PubMed. Results: In this work, 26 eligible studies with preclinical data encompassing more than 20 distinct nanotechnological platforms were reviewed. Most of the conclusions from these investigations were drawn from cell proliferation assays, primarily involving the PC cell lines PANC-1, MIA PaCa-2, and HPAF-II. A smaller subset of investigations supplemented these findings with data from xenograft PC models treated with phytochemical-loaded nanoformulations. Among the phytochemicals most frequently incorporated into the nanoformulations were paclitaxel, curcumin, lawsone, and sulforaphane. Conclusion: Phytochemical-containing nanoformulations hold considerable promise as innovative therapeutic alternatives for PC. However, many available studies present notable limitations, such as the use of preclinical models with limited translatability to humans and a lack of a standardized method for preparing nanoformulations. Therefore, further investigations are required to clarify the therapeutic efficacy, safety profile, pharmacodynamics, pharmacokinetics, and overall clinical potential of these nanotechnology-driven approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.